These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

864 related items for PubMed ID: 21855548

  • 1. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
    Repp R, Kellner C, Muskulus A, Staudinger M, Nodehi SM, Glorius P, Akramiene D, Dechant M, Fey GH, van Berkel PH, van de Winkel JG, Parren PW, Valerius T, Gramatzki M, Peipp M.
    J Immunol Methods; 2011 Oct 28; 373(1-2):67-78. PubMed ID: 21855548
    [Abstract] [Full Text] [Related]

  • 2. Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.
    Ferrara C, Brünker P, Suter T, Moser S, Püntener U, Umaña P.
    Biotechnol Bioeng; 2006 Apr 05; 93(5):851-61. PubMed ID: 16435400
    [Abstract] [Full Text] [Related]

  • 3. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):93-103. PubMed ID: 16236307
    [Abstract] [Full Text] [Related]

  • 4. Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded bispecific antibody comprising of two single-chain antibodies linked to the antibody constant region.
    Natsume A, Wakitani M, Yamane-Ohnuki N, Shoji-Hosaka E, Niwa R, Uchida K, Satoh M, Shitara K.
    J Biochem; 2006 Sep 30; 140(3):359-68. PubMed ID: 16861252
    [Abstract] [Full Text] [Related]

  • 5. Identification of IgG(1) variants with increased affinity to FcγRIIIa and unaltered affinity to FcγRI and FcRn: comparison of soluble receptor-based and cell-based binding assays.
    Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D, Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong WL, Meng YG.
    J Immunol Methods; 2011 Feb 28; 365(1-2):132-41. PubMed ID: 21185301
    [Abstract] [Full Text] [Related]

  • 6. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types.
    Kanda Y, Yamada T, Mori K, Okazaki A, Inoue M, Kitajima-Miyama K, Kuni-Kamochi R, Nakano R, Yano K, Kakita S, Shitara K, Satoh M.
    Glycobiology; 2007 Jan 28; 17(1):104-18. PubMed ID: 17012310
    [Abstract] [Full Text] [Related]

  • 7. Fc engineering: design, expression, and functional characterization of antibody variants with improved effector function.
    Derer S, Kellner C, Berger S, Valerius T, Peipp M.
    Methods Mol Biol; 2012 Jan 28; 907():519-36. PubMed ID: 22907372
    [Abstract] [Full Text] [Related]

  • 8. Correlation between CD16a binding and immuno effector functionality of an antigen specific immunoglobulin Fc fragment (Fcab).
    Kainer M, Antes B, Wiederkum S, Wozniak-Knopp G, Bauer A, Rüker F, Woisetschläger M.
    Arch Biochem Biophys; 2012 Oct 15; 526(2):154-8. PubMed ID: 22634259
    [Abstract] [Full Text] [Related]

  • 9. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density.
    Niwa R, Sakurada M, Kobayashi Y, Uehara A, Matsushima K, Ueda R, Nakamura K, Shitara K.
    Clin Cancer Res; 2005 Mar 15; 11(6):2327-36. PubMed ID: 15788684
    [Abstract] [Full Text] [Related]

  • 10. The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation.
    Shibata-Koyama M, Iida S, Okazaki A, Mori K, Kitajima-Miyama K, Saitou S, Kakita S, Kanda Y, Shitara K, Kato K, Satoh M.
    Glycobiology; 2009 Feb 15; 19(2):126-34. PubMed ID: 18952826
    [Abstract] [Full Text] [Related]

  • 11. A variant human IgG1-Fc mediates improved ADCC.
    Stewart R, Thom G, Levens M, Güler-Gane G, Holgate R, Rudd PM, Webster C, Jermutus L, Lund J.
    Protein Eng Des Sel; 2011 Sep 15; 24(9):671-8. PubMed ID: 21596686
    [Abstract] [Full Text] [Related]

  • 12. Enhanced ADCC activity of affinity maturated and Fc-engineered mini-antibodies directed against the AML stem cell antigen CD96.
    Mohseni Nodehi S, Repp R, Kellner C, Bräutigam J, Staudinger M, Schub N, Peipp M, Gramatzki M, Humpe A.
    PLoS One; 2012 Sep 15; 7(8):e42426. PubMed ID: 22879978
    [Abstract] [Full Text] [Related]

  • 13. Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII.
    Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M.
    Biotechnol Bioeng; 2001 Aug 20; 74(4):288-94. PubMed ID: 11410853
    [Abstract] [Full Text] [Related]

  • 14. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIaV158 Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages.
    Kang TH, Lee CH, Delidakis G, Jung J, Richard-Le Goff O, Lee J, Kim JE, Charab W, Bruhns P, Georgiou G.
    Front Immunol; 2019 Aug 20; 10():562. PubMed ID: 30984171
    [Abstract] [Full Text] [Related]

  • 15. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
    Borgerding A, Hasenkamp J, Engelke M, Burkhart N, Trümper L, Wienands J, Glass B.
    Exp Hematol; 2010 Mar 20; 38(3):213-21. PubMed ID: 20056126
    [Abstract] [Full Text] [Related]

  • 16. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa.
    Iida S, Misaka H, Inoue M, Shibata M, Nakano R, Yamane-Ohnuki N, Wakitani M, Yano K, Shitara K, Satoh M.
    Clin Cancer Res; 2006 May 01; 12(9):2879-87. PubMed ID: 16675584
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides.
    Niwa R, Natsume A, Uehara A, Wakitani M, Iida S, Uchida K, Satoh M, Shitara K.
    J Immunol Methods; 2005 Nov 30; 306(1-2):151-60. PubMed ID: 16219319
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Development of an ELISA based bridging assay as a surrogate measure of ADCC.
    Miller AS, Tejada ML, Gazzano-Santoro H.
    J Immunol Methods; 2012 Nov 30; 385(1-2):45-50. PubMed ID: 22914441
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.